CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
السعر · أغسطس 19, 2026
البيانات الأساسية اعتبارًا من أغسطس 3, 2026
نطاق 52 أسبوعًا
$29–$85
100% of range
تقييم المحللين
HOLD
21 analysts
السعر المستهدف
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
هامش صافي الربح
-6046.2%
حول Crinetics Pharmaceuticals, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
اقرأ المزيد
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
CRNX لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$84.77
القيمة السوقية
$8.10B
P/E (TTM)
-17.1
ربح السهم (آخر 12 شهرًا)
$-4.95
الإيرادات (آخر 12 شهرًا)
$8M
عائد التوزيعات
—
ROE
-43.0%
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$29 – $85
CRNX مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$8M
2016-12-31
→
2025-12-31
ربح السهم
$-4.95
2020-12-31
→
2025-12-31
التدفق النقدي الحر
$-384M
2018-12-31
→
2025-12-31
الهوامش
-6046.2%
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
CRNX
متوسط الأقران
P/E (TTM)
-17.1
47.9
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
1052.7
16.2
P/B (السعر / القيمة الدفترية)
8.2
9.3
Price / FCF (السعر / التدفق النقدي الحر)
-21.1
—
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
CRNX
متوسط الأقران
Operating Margin (هامش التشغيل)
-6714.8%
—
Net Profit Margin (هامش صافي الربح)
-6046.2%
5.1%
ROA (العائد على الأصول)
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
CRNX
متوسط الأقران
Current Ratio (النسبة الحالية)
12.3
2.7
Quick Ratio (النسبة السريعة)
12.1
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
CRNX
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
640.7%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
17.6%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
155.3%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
CRNX
متوسط الأقران
CRNX توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
احتفاظ
21 محللين
- شراء قوي 3 14,3%
- شراء 4 19,0%
- احتفاظ 14 66,7%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
10 محللين · 2026-08-13
الوسيط
$85.00
المتوسط
$85.50
← أقل من جميع الأهداف
$84.77
منخفض
$85.00
مرتفع
$90.00
السعر المستهدف الوسيط
$85.00
+0,3%
السعر المستهدف المتوسط
$85.50
+0,9%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
-0.01%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $-1.14 | $-1.23 | 0.09% |
| 31 مارس، 2026 | $-1.23 | $-1.26 | 0.03% |
| 31 ديسمبر، 2025 | $-1.29 | $-1.39 | 0.10% |
| 30 سبتمبر، 2025 | $-1.38 | $-1.28 | -0.10% |
| 30 يونيو، 2025 | $-1.23 | $-1.12 | -0.11% |
| 31 مارس، 2025 | $-1.04 | $-0.96 | -0.08% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
الميزانية العمومية 24
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
التدفق النقدي 13
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
السيولة والملاءة 2
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
معدلات النمو 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
قائمة الدخل 15
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
الميزانية العمومية 23
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
التدفق النقدي 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
الربحية 6
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
السيولة والملاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $8M | $1M | $4M | $5M | $1M |
| هامش الربح التشغيلي % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| صافي الدخل | $-465M | $-298M | $-215M | $-164M | $-108M |
| EPS المخفف | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| النسبة السريعة | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $-384M | $-230M | $-171M | $-117M | $-89M |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 286 مقدمي إقرار · $3.2B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 63 (+17 مقابل الربع السابق) | 30 (-14 مقابل الربع السابق) | 95 (-17 مقابل الربع السابق) | 63 (+3 مقابل الربع السابق) | +21.6M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| FMR LLC | $486250673 | 12994406 | 15,13% | الأسهم |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336372047 | 8989098 | 10,46% | الأسهم |
| Driehaus Capital Management LLC | $241866078 | 6463551 | 7,52% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $237002526 | 6333579 | 7,37% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180836416 | 4832614 | 5,63% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $177567704 | 4745262 | 5,52% | الأسهم |
| STATE STREET CORP | $100635477 | 2689350 | 3,13% | الأسهم |
| Bellevue Group AG | $98040400 | 2620000 | 3,05% | الأسهم |
| BAKER BROS. ADVISORS LP | $87991820 | 2351465 | 2,74% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $87542675 | 2338905 | 2,72% | الأسهم |
| Polar Capital Holdings Plc | $85108460 | 2274411 | 2,65% | الأسهم |
| Pictet Asset Management Holding SA | $77572984 | 2075375 | 2,41% | الأسهم |
| Siren, L.L.C. | $53165887 | 1420788 | 1,65% | الأسهم |
| First Light Asset Management, LLC | $50923606 | 1360866 | 1,58% | الأسهم |
| NOVO HOLDINGS A/S | $49394400 | 1320000 | 1,54% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $47245129 | 1262562 | 1,47% | الأسهم |
| ADAR1 Capital Management, LLC | $45730234 | 1222080 | 1,42% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $44555208 | 1190679 | 1,39% | الأسهم |
| MONTANOVA CAPITAL, LLC | $44390560 | 1186279 | 1,38% | الأسهم |
| ORBIMED ADVISORS LLC | $37382580 | 999000 | 1,16% | الأسهم |
| Hood River Capital Management LLC | $36259830 | 968996 | 1,13% | الأسهم |
| GOLDMAN SACHS GROUP INC | $34657132 | 926166 | 1,08% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32841401 | 877643 | 1,02% | الأسهم |
| Aberdeen Group plc | $30699181 | 820395 | 0,95% | الأسهم |
| Candriam S.C.A. | $30618690 | 819032 | 0,95% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $28230995 | 754436 | 0,88% | الأسهم |
| Fisher Asset Management, LLC | $27748912 | 741553 | 0,86% | الأسهم |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17709036 | 479400 | 0,55% | الأسهم |
| AMERIPRISE FINANCIAL INC | $17451149 | 466356 | 0,54% | الأسهم |
| Impax Asset Management Group plc | $16277700 | 435000 | 0,51% | الأسهم |
| Prosight Management, LP | $14020002 | 374666 | 0,44% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13991714 | 373910 | 0,44% | الأسهم |
| KENNEDY CAPITAL MANAGEMENT LLC | $13685018 | 365714 | 0,43% | الأسهم |
| BRAUN STACEY ASSOCIATES INC | $13027511 | 348143 | 0,41% | الأسهم |
| Fiera Capital Corp | $12395263 | 331247 | 0,39% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $11271877 | 301226 | 0,35% | الأسهم |
| Defilade Capital Management, L.P. | $8959845 | 239440 | 0,28% | الأسهم |
| SEB Asset Management AB | $8003786 | 213891 | 0,25% | الأسهم |
| Foresite Capital Management VI LLC | $7933414 | 212010 | 0,25% | الأسهم |
| RICE HALL JAMES & ASSOCIATES, LLC | $7346220 | 196318 | 0,23% | الأسهم |
| TD Asset Management Inc | $7152534 | 191142 | 0,22% | الأسهم |
| Swiss National Bank | $6877796 | 183800 | 0,21% | الأسهم |
| SEGALL BRYANT & HAMILL, LLC | $6855307 | 183199 | 0,21% | الأسهم |
| BlackRock, Inc. | $6781290 | 181221 | 0,21% | الأسهم |
| JENNISON ASSOCIATES LLC | $6056839 | 161861 | 0,19% | الأسهم |
| New Leaf Venture Partners, L.L.C. | $5872650 | 141000 | 0,18% | الأسهم |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5865136 | 156738 | 0,18% | الأسهم |
| Foresite Capital Management IV, LLC | $5613000 | 150000 | 0,17% | الأسهم |
| Bank of New York Mellon Corp | $5581754 | 149165 | 0,17% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $5508898 | 147218 | 0,17% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $5471384 | 146216 | 0,17% | الأسهم |
| Moody Aldrich Partners LLC | $5466201 | 146077 | 0,17% | الأسهم |
| Ishara Investments LP | $5369770 | 143500 | 0,17% | الأسهم |
| CITADEL ADVISORS LLC | $5176271 | 138329 | 0,16% | الأسهم |
| RHUMBLINE ADVISERS | $4861141 | 129908 | 0,15% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $4782618 | 131680 | 0,15% | الأسهم |
| GordonMD Global Investments LP | $4751779 | 126985 | 0,15% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4712974 | 125948 | 0,15% | الأسهم |
| JANUS HENDERSON GROUP PLC | $4700428 | 129392 | 0,15% | الأسهم |
| Cormorant Asset Management, LP | $4677500 | 125000 | 0,15% | الأسهم |
| SECTOR GAMMA AS | $4289380 | 114628 | 0,13% | الأسهم |
| XTX Topco Ltd | $4164547 | 111292 | 0,13% | الأسهم |
| ALPS ADVISORS INC | $3981825 | 106409 | 0,12% | الأسهم |
| FEDERATED HERMES, INC. | $3957390 | 105756 | 0,12% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3834048 | 105563 | 0,12% | الأسهم |
| Nuveen Asset Management, LLC | $3760151 | 73541 | 0,12% | الأسهم |
| Burkehill Global Management, LP | $3742000 | 100000 | 0,12% | الأسهم |
| Nuveen, LLC | $3619262 | 96720 | 0,11% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $3484251 | 93112 | 0,11% | الأسهم |
| MORGAN STANLEY | $3320829 | 88744 | 0,10% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $3266729 | 87299 | 0,10% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $3254754 | 86979 | 0,10% | الأسهم |
| AWM Investment Company, Inc. | $3180700 | 85000 | 0,10% | الأسهم |
| Odyssean, LLC | $3160344 | 84456 | 0,10% | الأسهم |
| Affinity Asset Advisors, LLC | $2806500 | 75000 | 0,09% | الأسهم |
| ALGERT GLOBAL LLC | $2714147 | 72532 | 0,08% | الأسهم |
| ExodusPoint Capital Management, LP | $2652404 | 70882 | 0,08% | الأسهم |
| Ensign Peak Advisors, Inc | $2507290 | 67004 | 0,08% | الأسهم |
| BARCLAYS PLC | $2466127 | 65904 | 0,08% | الأسهم |
| FIRST TRUST ADVISORS LP | $2370631 | 63352 | 0,07% | الأسهم |
| Man Group plc | $2284229 | 61043 | 0,07% | الأسهم |
| MetLife Investment Management, LLC | $2258709 | 60361 | 0,07% | الأسهم |
| CITIGROUP INC | $2255229 | 60268 | 0,07% | الأسهم |
| Longaeva Partners L.P. | $2184879 | 58388 | 0,07% | الأسهم |
| Swedbank AB | $2155392 | 57600 | 0,07% | الأسهم |
| STATE OF WISCONSIN INVESTMENT BOARD | $2068016 | 55265 | 0,06% | الأسهم |
| Jump Financial, LLC | $1923388 | 51400 | 0,06% | الأسهم |
| Lighthouse Investment Partners, LLC | $1871000 | 50000 | 0,06% | الأسهم |
| Vestmark Advisory Solutions, Inc. | $1823252 | 48724 | 0,06% | الأسهم |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1787254 | 47762 | 0,06% | الأسهم |
| VANGUARD GROUP INC | $1774626 | 38123 | 0,06% | الأسهم |
| Point72 Asset Management, L.P. | $1735577 | 46381 | 0,05% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $1696398 | 45334 | 0,05% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $1606254 | 42925 | 0,05% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1549188 | 41400 | 0,05% | عقد خيار الشراء |
| Invesco Ltd. | $1545446 | 41300 | 0,05% | الأسهم |
| Vanguard Global Advisers, LLC | $1485986 | 39711 | 0,05% | الأسهم |
| HighMark Wealth Management LLC | $1444224 | 38595 | 0,04% | الأسهم |
| OAK RIDGE INVESTMENTS LLC | $1405046 | 37548 | 0,04% | الأسهم |
| Orion Porfolio Solutions, LLC | $1404234 | 37526 | 0,04% | الأسهم |
المطلعون على الشركة 20 من المطلعين · مسؤولون 9 · مديرون 10
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10 مارس، 2025 A | 52000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26 سبتمبر، 2024 M | 111092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19 مارس، 2025 S | 87491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12 يونيو، 2025 M | 99713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19 مارس، 2025 S | 72233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10 يناير، 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 5 يوليو، 2024 M | 29259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17 أكتوبر، 2023 M | 43210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28 فبراير، 2022 A | 176995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | مدير | 2 يوليو، 2026 S | 19225 | 0 | 1 | $-120000 |
| Caren Deardorf | مدير | 18 يونيو، 2026 A | 22225 | 0 | 0 | $0 |
| Weston Nichols | مدير | 18 يونيو، 2026 A | 22225 | 0 | 0 | $0 |
| Stephanie Okey | مدير | 18 يونيو، 2026 A | 12325 | 0 | 2 | $-246143 |
| Matthew K Fust | مدير | 18 يونيو، 2026 A | 28761 | 0 | 0 | $0 |
| Camille L Bedrosian | مدير | 18 يونيو، 2026 A | 22225 | 0 | 0 | $0 |
| Wendell Wierenga | مدير | 18 يونيو، 2026 A | 122071 | 0 | 0 | $0 |
| Wendall Wierenga | مدير | 11 يونيو، 2025 A | 116146 | 0 | 0 | $0 |
| Stephen W Kaldor | مدير | 19 يونيو، 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | مدير | 21 يونيو، 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 7 أغسطس، 2026 M | 424706 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 1 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 إيداعات | 1 مارس، 2024 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 55 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107892 NS | 31 مايو، 2026 | N-PORT |
| IHE · iShares Trust | 1,95% | 376636 SH | 8 أغسطس، 2026 | يومي |
| FMED · Fidelity Covington Trust | 1,65% | 19000 NS | 31 مايو، 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4666 NS | 30 إبريل، 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18743 NS | 30 إبريل، 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11043 NS | 31 مايو، 2026 | N-PORT |
| IBB · iShares Trust | 0,63% | 718323 SH | 8 أغسطس، 2026 | يومي |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 5737 SH | 8 أغسطس، 2026 | يومي |
| IWO · iShares Trust | 0,54% | 940202 SH | 8 أغسطس، 2026 | يومي |
| NUSC · Nushares ETF Trust | 0,28% | 93045 NS | 30 إبريل، 2026 | N-PORT |
| ISCG · iShares Trust | 0,27% | 32694 SH | 8 أغسطس، 2026 | يومي |
| IWM · iShares Trust | 0,27% | 2625192 SH | 8 أغسطس، 2026 | يومي |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,23% | 110770 SH | 8 أغسطس، 2026 | يومي |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38553 NS | 30 إبريل، 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3872 NS | 31 مايو، 2026 | N-PORT |
| ESML · iShares Trust | 0,16% | 55438 SH | 8 أغسطس، 2026 | يومي |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3142 NS | 30 إبريل، 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 51135 SH | 8 أغسطس، 2026 | يومي |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18879 NS | 30 إبريل، 2026 | N-PORT |
| ISCB · iShares Trust | 0,13% | 4625 SH | 8 أغسطس، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,12% | 596648 SH | 8 أغسطس، 2026 | يومي |
| RSSL · Global X Funds | 0,12% | 42391 NS | 30 إبريل، 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,11% | 1399667 SH | 8 أغسطس، 2026 | يومي |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31759 NS | 30 إبريل، 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4601 NS | 31 مايو، 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,09% | 2909 SH | 8 أغسطس، 2026 | يومي |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492431 NS | 31 مايو، 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24991 NS | 30 إبريل، 2026 | N-PORT |
| WSML · iShares Trust | 0,07% | 5742 SH | 8 أغسطس، 2026 | يومي |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41183 NS | 30 إبريل، 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196549 NS | 30 إبريل، 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3599 NS | 31 مايو، 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,05% | 2419186 SH | 8 أغسطس، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | 0,05% | 275155 SH | 8 أغسطس، 2026 | يومي |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5196 NS | 30 إبريل، 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1210574 SH | 8 أغسطس، 2026 | يومي |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31 مايو، 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3643 NS | 31 مايو، 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5689 NS | 31 مايو، 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3773 NS | 31 مايو، 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31 مايو، 2026 | N-PORT |
| ITOT · iShares Trust | 0,01% | 146419 SH | 8 أغسطس، 2026 | يومي |
| IWV · iShares Trust | 0,01% | 27043 SH | 8 أغسطس، 2026 | يومي |
| DFAC · Dimensional ETF Trust | 0,01% | 125853 NS | 30 إبريل، 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 3342704 SH | 8 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8345 SH | 8 أغسطس، 2026 | يومي |
| ESGV · VANGUARD WORLD FUND | 0,01% | 22843 SH | 8 أغسطس، 2026 | يومي |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28694 NS | 31 مايو، 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5863 NS | 30 إبريل، 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3388 NS | 30 إبريل، 2026 | N-PORT |